The goal of this clinical trial is to learn whether microbiome analysis, education, and personalized recommendations can improve gut health and reduce early markers of immune-related conditions in infants aged 0-3 months delivered via Cesarean section. The study aims to determine whether these interventions can increase beneficial bacteria, decrease C-section-associated microbiome signatures, reduce opportunistic pathogens, and improve functional potential for HMO digestion and SCFA production. The study also seeks to assess whether improvements in microbiome composition are associated with a reduced prevalence of early atopic symptoms.

Researchers will compare three groups: a full intervention arm that receives microbiome reports, coaching, personalized recommendations, and educational materials; a limited intervention arm that receives simplified reports and basic recommendations; and a control arm that receives no results until study completion. This design allows evaluation of both a comprehensive intervention and a more scalable, minimal-results model.

Participants will:

1. Provide six microbiome stool samples over a 24-month period.
2. Provide additional small stool samples at two timepoints for exploratory metabolomic analysis.
3. Receive microbiome reports and guidance according to their assigned study arm.
4. Complete surveys on infant health history, symptoms, diet, and environmental exposures.
5. Participate in standardized eczema assessment(s) administered by a Nurse Practitioner and evaluated by a Pediatric Allergy Specialist if any symptoms are reported.

This study seeks to demonstrate that targeted microbiome support can positively shift gut microbial development in C-section infants and may reduce risks linked to the early stages of the atopic march. Findings may inform scalable strategies for delivering microbiome-based support in early life and improve long-term health outcomes for this high-risk population.

Flourish: Exploring the Early Infant Gut Microbiome

Seeding Inc

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

San Antonio, Texas

San Antonio, TX

Bellaire, TX

McGovern Medical School - ACTAT - Research Department

Texas Medical Center

Dallas, TX

Plano, TX

Oklahoma City, OK

Hot Springs, AR

Tulsa, OK

North Little Rock

Albuquerque, NM

Dermatology and Skin Cancer Center Leawood

SLUCare Academic Pavilion - Endocrinology Division Research

Lincoln, NE

Research Center

Scottsdale, AZ

West Lafayette, Indiana

Indianapolis, IN

Cape Coral, FL

Rapid City, SD

Charlotte, NC

Bexley, OH

Las Vegas, NV

Miami Lakes, FL

Miami, FL

Boca Raton, FL

Hialeah, FL

Coral Gables, FL

Windsor, Canada

Troy, MI

Derm Center

Long Beach, CA

Los Angeles, CA

Santa Monica, CA

Northridge, CA

Canoga Park, California

Bakersfield, CA

Internal Medicine Glennan Center for Geriatrics and Gerontology

Waterloo, Canada

Chevy Chase, MD

Hamilton, Canada

Burlington, Canada

Oakvile, Canada

Towson, MD

Mississauga, Canada

Niagara Falls, Canada

Camp Hill, PA

Etobicoke, Canada

Toronto, Canada

Boise, ID

Ontario, Canada

Richmond Hill, CA

Richmond Hill, Canada

Ontario, CA

Newmarket, Canada

Ajax, Canada

Reno - Moana Lane Location

Sacramento, CA

Dublin, CA

Department of Cardiology

New York, NY

Jose Garcia, Coordinator

Forest Hills Dermatology Group

Saskatoon, Canada

Ottawa, Canada

Clinical Research Institute of Southern Oregon (CRISOR)

Calgary, Canada

Clinical Operations Department

Portland, OR

Kelowna, Canada

 Edmonton, Canada

Vida Dermatology South

San Juan, PR

St. Johns, NL

Santiago, Chile

Rosario, Argentina

Maldegem, Belgium

Kortrijk, Belgium

Clinical Research Unit

Buenos Aires, Argentina

Remscheid, Germany

Hannover, Germany

Leipzig, Germany

Haematology Department

Tartu, Estonia

Clinical Trial Center

Lublin, Poland

Szolnok, Hungary

Nagoya City University Hospital

Benowa, Australia

Carlton, Australia

Amgen

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.

Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib 15mg or dupilumab 300mg. Based on the participants response to upadacitinib 15mg, they may have their dose increased to upadacitinib 30mg after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 200 adult participants ages 18 to less than 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 130 sites worldwide.

The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Austin, TX

Cypress, TX

Sugar Land, TX

Arlington, TX

Mesquite, TX

Saint Joseph, MO

Dawsonville, GA

Tampa, FL

Jacksonville, FL

Coral Springs - Oncology

Margate, FL

 Thousand Oaks, CA

Plymouth Meeting, PA

Quincy, MA

AbbVie

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Galderma

Find clinical trials for Eczema in Austin, TX

Related conditions:

Eczema trials near Austin, TX, USA:

Flourish: Exploring the Early Infant Gut Microbiome

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in .css-epvm6{white-space:nowrap;}Austin, TX

Related conditions:

Eczema trials near Austin, TX, USA:

Flourish: Exploring the Early Infant Gut Microbiome

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Find clinical trials for Eczema in Austin, TX